Sectors & IndustriesHealthcareDrug Manufacturers - Specialty & Generic
Best Pharmaceutical Stocks to Buy Now (2025)
Top pharmaceutical stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best pharmaceutical stocks to buy now. Learn More.

Industry: Drug Manufacturers - Spec...
C
Pharmaceutical is Zen Rated C and is the 59th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Sentiment
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
PAHC
PHIBRO ANIMAL HEALTH CORP
$972.81M40,533,60843.29%56.71%Net BuyingNet Buying
CPIX
CUMBERLAND PHARMACEUTICALS INC
$70.47M14,961,13728.28%55.80%Net BuyingNet Buying
AMRX
AMNEAL PHARMACEUTICALS INC
$2.38B313,419,59926.05%73.95%Net SellingNet Selling
KMDA
KAMADA LTD
$399.08M57,505,0318.53%0.00%
HCM
HUTCHMED (CHINA) LTD
$2.33B871,601,0950.75%0.00%
COLL
COLLEGIUM PHARMACEUTICAL INC
$971.66M32,142,19256.72%43.28%Net SellingNet Selling
INDV
INDIVIOR PLC
$1.41B124,769,53372.51%0.00%
AVDL
AVADEL PHARMACEUTICALS PLC
$871.62M96,738,93580.23%13.61%Net Buying
ANIP
ANI PHARMACEUTICALS INC
$1.30B21,661,93529.15%70.85%Net SellingNet Selling
SUPN
SUPERNUS PHARMACEUTICALS INC
$1.87B55,989,62346.04%53.96%Net SellingNet Selling
ETON
ETON PHARMACEUTICALS INC
$507.66M26,817,53551.16%22.99%Net Buying
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
$19.43B1,146,959,85561.66%0.78%Net SellingNet Selling
EBS
EMERGENT BIOSOLUTIONS INC
$360.40M54,277,82741.40%58.60%Net SellingNet Buying
DERM
JOURNEY MEDICAL CORP
$161.56M23,295,76920.77%35.05%Net SellingNet Selling
HLN
HALEON PLC
$49.05B9,083,725,9196.41%0.00%
PRGO
PERRIGO CO PLC
$3.72B137,477,30662.13%37.87%Net BuyingNet Buying
ZTS
ZOETIS INC
$72.59B445,208,05390.99%5.78%Net SellingNet Selling
PCRX
PACIRA BIOSCIENCES INC
$1.20B46,304,66768.60%31.40%Net Selling
SNOA
SONOMA PHARMACEUTICALS INC
$5.22M1,615,7650.86%99.14%
ALVO
ALVOTECH
$3.16B301,805,6775.51%0.00%
PBH
PRESTIGE CONSUMER HEALTHCARE INC
$4.40B49,414,70768.87%31.13%Net SellingNet Selling
TKNO
ALPHA TEKNOVA INC
$353.51M53,440,81011.49%63.97%Net Buying
NBIX
NEUROCRINE BIOSCIENCES INC
$11.98B98,965,82069.88%30.12%Net SellingNet Buying
ELAN
ELANCO ANIMAL HEALTH INC
$6.42B496,646,50490.54%9.46%Net SellingNet Selling
BHC
BAUSCH HEALTH COMPANIES INC
$1.73B369,550,08665.70%30.82%Net SellingNet Selling
ACB
AURORA CANNABIS INC
$281.52M54,877,90514.43%0.00%
LNTH
LANTHEUS HOLDINGS INC
$5.62B69,185,83656.14%43.86%Net SellingNet Selling
IRWD
IRONWOOD PHARMACEUTICALS INC
$92.24M161,819,84870.25%29.75%Net Selling
ALKS
ALKERMES PLC
$5.18B164,901,28593.19%6.81%Net SellingNet Selling
CRON
CRONOS GROUP INC
$824.80M385,419,02111.41%48.72%Net SellingNet Selling
SIGA
SIGA TECHNOLOGIES INC
$427.93M71,441,08335.95%64.05%Net SellingNet Selling
VTRS
VIATRIS INC
$10.38B1,173,681,96480.99%18.14%Net SellingNet Selling
DVAX
DYNAVAX TECHNOLOGIES CORP
$1.16B120,080,65065.24%34.76%Net SellingNet Selling
OGI
ORGANIGRAM GLOBAL INC
$182.02M133,835,9634.61%0.00%
RDY
DR REDDYS LABORATORIES LTD
$12.04B834,091,33012.95%0.00%
AMPH
AMPHASTAR PHARMACEUTICALS INC
$1.17B47,139,08548.73%51.27%Net BuyingNet Buying
RGC
REGENCELL BIOSCIENCE HOLDINGS LTD
$5.11B13,012,8660.07%0.00%
CPHI
CHINA PHARMA HOLDINGS INC
$7.24M3,262,0020.64%99.36%
ORGO
ORGANOGENESIS HOLDINGS INC
$390.71M126,853,5366.04%93.96%Net SellingNet Selling
EOLS
EVOLUS INC
$625.41M64,475,58975.29%24.71%Net SellingNet Selling
TAK
TAKEDA PHARMACEUTICAL CO LTD
$44.41B1,573,649,6464.51%0.00%
EVO
EVOTEC SE
$1.44B177,553,4565.13%0.00%
BIOA
BIOAGE LABS INC
$141.25M35,850,03756.47%24.78%Net Buying
RMTI
ROCKWELL MEDICAL INC
$34.52M34,174,68716.67%83.33%Net BuyingNet Buying
HROW
HARROW INC
$1.04B36,699,55328.33%71.67%Net SellingNet Selling
APUS
APIMEDS PHARMACEUTICALS US INC
N/A12,693,3980.00%49.56%Net BuyingNet Buying
SBFM
SUNSHINE BIOPHARMA INC
$4.06M2,707,5411.94%98.06%
KALA
KALA BIO INC
$23.68M6,452,3987.61%92.39%Net Buying
ASRT
ASSERTIO HOLDINGS INC
$63.79M95,780,74126.42%21.22%Net BuyingNet Selling
SXTC
CHINA SXT PHARMACEUTICALS INC
$4.69M3,906,4710.13%0.00%
LFCR
LIFECORE BIOMEDICAL INC
$255.29M37,025,33148.07%51.93%Net BuyingNet Selling
CRDL
CARDIOL THERAPEUTICS INC
$91.70M82,608,9928.71%0.00%
CGC
CANOPY GROWTH CORP
$244.22M147,120,08810.04%72.04%Net SellingNet Selling
ESPR
ESPERION THERAPEUTICS INC
$158.96M198,199,46257.17%20.63%Net SellingNet Selling
QNTM
QUANTUM BIOPHARMA LTD
$27.79M2,711,0852.58%0.00%
UPC
UNIVERSE PHARMACEUTICALS INC
$129.82M23,645,9740.98%0.00%
PRFX
PAINREFORM LTD
$2.81M1,471,4120.05%0.00%
AQST
AQUESTIVE THERAPEUTICS INC
$236.40M99,327,92844.51%7.79%Net SellingNet Selling
GELS
GELTEQ LTD
$18.03M9,438,0751.11%0.00%
BFRI
BIOFRONTERA INC
$6.14M9,446,19715.37%84.63%
AYTU
AYTU BIOPHARMA INC
$13.14M6,170,2465.92%94.08%Net BuyingNet Buying
EVOK
EVOKE PHARMA INC
$4.81M1,492,8582.02%97.98%Net BuyingNet Buying
IMCC
IM CANNABIS CORP
$5.12M3,085,4523.87%0.00%
INCR
INTERCURE LTD
$71.45M47,162,7135.27%0.00%
RDHL
REDHILL BIOPHARMA LTD
$0.0012,899,831,0000.00%0.00%
CTOR
CITIUS ONCOLOGY INC
$64.68M71,552,4020.15%96.54%
TLPH
TALPHERA INC
$10.33M20,503,46311.45%88.55%Net BuyingNet Buying
TLRY
TILRAY BRANDS INC
$498.22M1,006,495,9268.89%1.77%Net Buying
YCBD
CBDMD INC
$801.64k782,8540.89%99.11%
PTPI
PETROS PHARMACEUTICALS INC
$4.14M31,160,0863.63%25.16%
TXMD
THERAPEUTICSMD INC
$17.36M11,574,3623.66%96.34%Net BuyingNet Buying
BGM
BGM GROUP LTD
$90.62M7,226,4801.30%0.00%
OPTN
OPTINOSE INC
$98.13M10,127,38117.90%82.10%Net SellingNet Selling
IXHL
INCANNEX HEALTHCARE INC
$7.65M29,433,7981.71%15.45%
SCYX
SCYNEXIS INC
$30.80M38,981,06428.64%22.75%Net BuyingNet Buying
SHPH
SHUTTLE PHARMACEUTICALS HOLDINGS INC
$2.37M10,984,2912.05%86.52%
FLGC
FLORA GROWTH CORP
$15.26M22,568,6532.41%41.74%Net Buying
DRRX
DURECT CORP
$19.56M31,042,5818.62%91.38%
AKAN
AKANDA CORP
$2.46M2,047,3320.56%0.00%

Pharmaceutical Stocks FAQ

What are the best pharmaceutical stocks to buy right now in May 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best pharma stocks to buy right now are:

1. Phibro Animal Health (NASDAQ:PAHC)


Phibro Animal Health (NASDAQ:PAHC) is the #1 top pharmaceutical stock out of 79 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Phibro Animal Health (NASDAQ:PAHC) is: Value: A, Growth: A, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: B.

Phibro Animal Health (NASDAQ:PAHC) has a Due Diligence Score of 42, which is 17 points higher than the pharmaceutical industry average of 25.

PAHC passed 15 out of 38 due diligence checks and has strong fundamentals. Phibro Animal Health has seen its stock return 33.48% over the past year, overperforming other pharmaceutical stocks by 80 percentage points.

Phibro Animal Health has an average 1 year price target of $21.50, a downside of -10.42% from Phibro Animal Health's current stock price of $24.00.

Phibro Animal Health stock has a consensus Sell recommendation according to Wall Street analysts. Of the 2 analysts covering Phibro Animal Health, 0% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 50% have issued a Strong Sell.

2. Cumberland Pharmaceuticals (NASDAQ:CPIX)


Cumberland Pharmaceuticals (NASDAQ:CPIX) is the #2 top pharmaceutical stock out of 79 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Cumberland Pharmaceuticals (NASDAQ:CPIX) is: Value: B, Growth: A, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: D.

Cumberland Pharmaceuticals (NASDAQ:CPIX) has a Due Diligence Score of 26, which is 1 points higher than the pharmaceutical industry average of 25.

CPIX passed 8 out of 33 due diligence checks and has average fundamentals. Cumberland Pharmaceuticals has seen its stock return 214% over the past year, overperforming other pharmaceutical stocks by 261 percentage points.

3. Amneal Pharmaceuticals (NASDAQ:AMRX)


Amneal Pharmaceuticals (NASDAQ:AMRX) is the #3 top pharmaceutical stock out of 79 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Amneal Pharmaceuticals (NASDAQ:AMRX) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: C, and AI: C.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a Due Diligence Score of 17, which is -8 points lower than the pharmaceutical industry average of 25. Although this number is below the industry average, our proven quant model rates AMRX as a "A".

AMRX passed 6 out of 33 due diligence checks and has weak fundamentals. Amneal Pharmaceuticals has seen its stock return 12.59% over the past year, overperforming other pharmaceutical stocks by 60 percentage points.

Amneal Pharmaceuticals has an average 1 year price target of $11.50, an upside of 51.32% from Amneal Pharmaceuticals's current stock price of $7.60.

Amneal Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Amneal Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the pharmaceutical stocks with highest dividends?

Out of 8 pharmaceutical stocks that have issued dividends in the past year, the 3 pharmaceutical stocks with the highest dividend yields are:

1. Siga Technologies (NASDAQ:SIGA)


Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 10.02%, which is 7 percentage points higher than the pharmaceutical industry average of 2.95%.

Siga Technologies's dividend payout ratio of 88.2% indicates that its high dividend yield is sustainable for the long-term.

2. Perrigo Co (NYSE:PRGO)


Perrigo Co (NYSE:PRGO) has an annual dividend yield of 3.11%, which is the same as the pharmaceutical industry average of 2.95%. Perrigo Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Perrigo Co's dividend has shown consistent growth over the last 10 years.

Perrigo Co's dividend payout ratio of -85.6% indicates that its dividend yield might not be sustainable for the long-term.

3. Kamada (NASDAQ:KMDA)


Kamada (NASDAQ:KMDA) has an annual dividend yield of 2.88%, which is the same as the pharmaceutical industry average of 2.95%.

Kamada's dividend payout ratio of 71.4% indicates that its dividend yield is sustainable for the long-term.

Why are pharmaceutical stocks up?

Pharmaceutical stocks were up 0.66% in the last day, and up 3.66% over the last week.

We couldn't find a catalyst for why pharmaceutical stocks are up.

What are the most undervalued pharmaceutical stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued pharmaceutical stocks right now are:

1. Ironwood Pharmaceuticals (NASDAQ:IRWD)


Ironwood Pharmaceuticals (NASDAQ:IRWD) is the most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 0, which is -12 points higher than the pharmaceutical industry average of 12. It passed 0 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates IRWD a Valuation Rating of "A".

Ironwood Pharmaceuticals's stock has dropped -91.42% in the past year. It has underperformed other stocks in the pharmaceutical industry by -44 percentage points.

2. Bausch Health Companies (NYSE:BHC)


Bausch Health Companies (NYSE:BHC) is the second most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bausch Health Companies has a valuation score of 0, which is -12 points higher than the pharmaceutical industry average of 12. It passed 0 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates BHC a Valuation Rating of "A".

Bausch Health Companies's stock has dropped -33.95% in the past year. It has overperformed other stocks in the pharmaceutical industry by 13 percentage points.

3. Collegium Pharmaceutical (NASDAQ:COLL)


Collegium Pharmaceutical (NASDAQ:COLL) is the third most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Collegium Pharmaceutical has a valuation score of 43, which is 31 points higher than the pharmaceutical industry average of 12. It passed 3 out of 7 valuation due diligence checks.

Collegium Pharmaceutical's stock has dropped -10.22% in the past year. It has overperformed other stocks in the pharmaceutical industry by 37 percentage points.

Are pharmaceutical stocks a good buy now?

41.46% of pharmaceutical stocks rated by analysts are a strong buy right now. On average, analysts expect pharmaceutical stocks to rise by 43.21% over the next year.

6.9% of pharmaceutical stocks have a Zen Rating of A (Strong Buy), 17.24% of pharmaceutical stocks are rated B (Buy), 53.45% are rated C (Hold), 15.52% are rated D (Sell), and 6.9% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - specialty & generic industry?

The average P/E ratio of the drug manufacturers - specialty & generic industry is 1.77x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.